Notably, two clinical trials of EP4 antagonists (Grapiprant and AN0025) combined with immune checkpoint therapy (pembrolizumab) in patients with advanced or progressive MSS colorectal cancer are currently under way (Grapiprant: NCT03658772; AN0025: NCT04432857). This evidence concerns the gene PTGER4 and Marinesco-Sjogren syndrome.